Nerve Sheath Neoplasms: Clinical Trials

8 trials for Nerve Sheath Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 withdrawn, 1 active not recruiting, 1 unknown. 8 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 48Completed 3, Withdrawn 3, Active not recruiting 1, Unknown 1

Follow Nerve Sheath Neoplasms: new trials by email Literature Review of Nerve Sheath Neoplasms trials Research Report on Nerve Sheath Neoplasms

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Neuroma Perfusion with Indocyanine Green Fluorescence Angiography
Indocyanine green - Neuroma, Neuroma Amputation
Phase 4WithdrawnNorthwestern University2024-12-282025-01-01
The ACTS Trial: N-acetylcysteine (NAC) and Night-splinting as a Non-operative Treatment for Carpal Tunnel Syndrome
N-Acetyl cysteine, Wrist Splint - Carpal Tunnel Syndrome, Hand Injuries and Disorders
Phase 4UnknownEmily Krauss2402022-04-012024-08-23
Pediatric Long-Term Follow-up and Rollover Study
dabrafenib, trametinib - Diffuse Astrocytoma, Anaplastic Astrocytoma
Phase 4Active not recruitingNovartis Pharmaceuticals1632019-11-042026-08-27
Dexmedetomidine and Propofol for Pediatric MRI Sedation
propofol, Dexmedetomidine, Glycopyrrolate - Headache, Tumor
Phase 4CompletedMedical College of Wisconsin402018-03-042020-02-21
Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function
Gentamicin - Vestibular Schwannoma
Phase 4WithdrawnLund University2015-04-012020-09-11
Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function
Gentamicins - Vestibular Schwannoma
Phase 4WithdrawnLund University2015-01-012020-09-11
Pathophysiology of Post Amputation Pain
Bupivacaine, Placebo - Amputation Stumps, Neuroma
Phase 4CompletedShirley Ryan AbilityLab162012-05-012015-07-21
NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate
methylphenidate - Neurofibromatosis Type 1
Phase 4CompletedHospices Civils de Lyon802004-01-012011-01-27

Narrower conditions

Neuroma (3)  ·  Neurofibromatosis 1 (2)  ·  Neuroma, Acoustic (2)  ·  Abdominal Neoplasms (1)  ·  Astrocytoma (1)  ·  Carpal Tunnel Syndrome (1)  ·  Disease (1)  ·  Epilepsy (1)  ·  Ganglioglioma (1)  ·  Ganglioneuroma (1)  ·  Glioblastoma (1)  ·  Glioma (1)  ·  Hand Injuries (1)  ·  Headache (1)  ·  Histiocytosis, Langerhans-Cell (1)

Broader conditions

Neoplasms by Histologic Type (8)  ·  Neoplasms, Nerve Tissue (8)  ·  Neoplasms (7)  ·  Nervous System Diseases (6)  ·  Neoplasms by Site (4)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Genetic Diseases, Inborn (3)  ·  Heredodegenerative Disorders, Nervous System (3)  ·  Neoplasms, Germ Cell and Embryonal (3)  ·  Neoplastic Syndromes, Hereditary (3)  ·  Nervous System Neoplasms (3)  ·  Neurocutaneous Syndromes (3)  ·  Neurodegenerative Diseases (3)  ·  Neuroectodermal Tumors (3)

Interventions

Gentamicins (2)  ·  Acetylcysteine (1)  ·  Bupivacaine (1)  ·  Dexmedetomidine (1)  ·  Dry Needling (1)  ·  Glycopyrrolate (1)  ·  Indocyanine Green (1)  ·  Lidocaine (1)  ·  Methylphenidate (1)  ·  Nitrous Oxide (1)  ·  Propofol (1)  ·  Sevoflurane (1)  ·  dabrafenib (1)  ·  trametinib (1)

Sponsors

Lund University (2)  ·  Emily Krauss (1)  ·  Hospices Civils de Lyon (1)  ·  Medical College of Wisconsin (1)  ·  Northwestern University (1)  ·  Novartis Pharmaceuticals (1)  ·  Shirley Ryan AbilityLab (1)

Countries

United States (4)  ·  Sweden (3)  ·  Canada (2)  ·  France (2)  ·  Argentina (1)  ·  Australia (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Finland (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)

Top investigators

Gregory A Dumanian, MD (1)  ·  Michael Bezuhly, MD (1)  ·  Norman Harden, M.D. (1)  ·  Susan P Taylor, MD, MPH (1)

Results publications

PMID 17917842, PMID 19574236, PMID 19645909, PMID 22027076, PMID 18607963, PMID 25205361

NIH funding

2023 (1)